PATENT CLAIM ANALYSIS

Application Number: 15766667
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "300000"]

Abstract:
The present disclosure is directed to disclosed compounds that modulate, e.g., address underlying defects in cellular processing of CFTR activity.

Claim (Index 57):
The method of  claim 56 , wherein at least one CFTR corrector or potentiator is independently selected from the group consisting of VX-152, VX-440, VX-770 (ivacaftor), VX-809 (lumacaftor) (3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid, VX-661 ((R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropane-1-carboxamide), VX-983, QBW251, GLPG2222, GLPG2851, GLPG2665, GLPG2737, FDL169, GLPG2451, GLPG1837, and genistein.

Metadata:
- Claim Count in Document: 140.0
- Percentile: 91.0
- Lexical Diversity: 1.04545
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15747290', '15539392', '16091401', '15539397', '15320172']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8352811957652005
- 35 USC 102 Novelty (BERT): 0.5325105426864948
- Combined Prediction Score: 0.80500413045733
- Mean Citation Score: 357.125496
- Max Citation Score: 371.4623
- Similarity Product: 257.97949325170515

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test